ZIOPHARM Oncology Inc. (NASDAQ:ZIOP)
ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) traded on unusually massive volume in yesterday’s trading session, as the stock lost almost 6% to close at $5.87. The stock witnessed 2.04 million shares traded on 9,729 trades. The stock’s average daily volume stood at 1.14 million shares per day in the previous last month, which indicates yesterday trading recorded significant jump in volume over the norm.
Usually, when a stock witness a sudden increase in trading volume, it is noted as a reversal signal for investors. A jump in volume indicates increased market awareness for the firm, potentially establishing a more meaningful move in shares price. The added volume provides a level of stability and support for price advances.
Over the last 52-weeks, the stock range was $9.19 and $4.45, its 50-day SMA is $6.24, while 200-day SMA is $5.88.
The financial performance
ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) released financial report for the fourth quarter closed December 2016, and released an update on the firm’s recent activities. Laurence Cooper, M.D., Ph.D., the CEO of ZIOPHARM, reported that the company has recorded substantial progress over the last year, putting them on track to start a pivotal trial and prosecute numerous high-value trials across oncology programs in 2017, bringing focus on gene treatment, TCR T-cell and CAR therapies, and off-the-shelf NK cells.
This strategy moves ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) not merely into a registration course with Ad-RTS-hIL-12 + veledimex, but clinically authorizes the broad prospect of technologies, including the switch setup and the Sleeping Beauty non-viral base. These advances will be put across program areas, allowing them to increase control, manage costs and reduce complexity, addressing some of the major considerable needs in cell and gene treatment. Ultimately, the ability to offer controlled, point-of-care treatment turns individualized treatment aiming each subject’s tumor neoantigens possible, an objective with deep clinical implications.
Francois Lebel, M.D., EVP, R&D, CMO at ZIOPHARM, added that in a recent presentation of report from Phase I, multi-center trial of Ad-RTS-hIL-12 and veledimex in subjects with recurrent high-grade gliomas, the median overall survival noted was 12.7 months in the ‘20mg veledimex’ dose group. It remains an encouraging outcome against historic controls. They anticipate offering an update on their registration course in this indication in Q1 2017, and to starting a pivotal trial by the close of 2017.
In Q4 2016, net loss was $14.8 million against a net loss of $9.5 million for Q4 2015. The jump in net loss for the quarter closed December 2016 is mainly due increase in expenses linked to the cell therapy and gene therapy programs, lower collaboration revenue, change in charge of derivative liabilities and income attributable to ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) preferred stockholders.
|Last Price a/o 3:21 PM EST||$5.87|
|Market Cap (mlns)||$777.07M|
|Shares Outstanding (mlns)||132.38M|
|Share Float (mlns)||127.91M|
|Short Interest Ratio||26.66|
I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 96 hours. All information, or data, is provided with no guarantees of accuracy.
About the author: Monica Gray has an undergraduate degree in Accounting and an MBA – earned with Honors. She has six years of experience in the financial markets and has been a securities analyst for the past two years.